BDKRB2 and malignant glioma: Based on our reasoning, we investigated the systemic actions of labradimil, as well as other bradykinin B2 receptor agonists with a range of known metabolic stabilities, in context of the local actions of the respective B2 receptor agonists on the BBTB of rodent malignant gliomas.